Latigo Biotherapeutics, Inc. (LTGO) reports that funds affiliated with 5AM converted preferred shares into common stock in connection with Latigo’s initial public offering. On August 10, 2026, 5AM Ventures VI, L.P. and 5AM Opportunities II, L.P. converted their Series A, Series A-2 and Series B Preferred Stock into an aggregate of common shares on a one-for-one basis for no additional consideration, leaving the preferred positions at zero. Following these automatic conversions immediately prior to the IPO closing, 5AM Ventures VI, L.P. holds 4,975,543 common shares indirectly and 5AM Opportunities II, L.P. holds 2,350,419 common shares indirectly. Control and beneficial ownership are described through 5AM’s general partner entities, with Dr. Kush Parmar and Andrew J. Schwab disclaiming beneficial ownership except to the extent of their pecuniary interests.
Latigo Biotherapeutics, Inc. (LTGO) received a Form 4 from several affiliated Foresite Capital funds, all reporting as ten percent owners. On August 10, 2026, they reported the conversion of 9,041,328 derivative securities (preferred stock and a convertible note) into an equal number of common shares, largely in connection with Latigo’s initial public offering as described in the footnotes. The same day, an affiliated fund also purchased 140,000 shares of common stock at $18.00 per share, all held indirectly through the funds, with each reporting person disclaiming beneficial ownership beyond its pecuniary interest.
Latigo Biotherapeutics, Inc. (LTGO) reported that director Todd N. Smith received a grant of stock options for 105,542 shares of common stock. The options have an exercise price of $18.00 per share, expire on August 5, 2036, and were acquired as a director stock option award. All 105,542 options are held directly and will vest in 36 equal monthly installments after May 30, 2026.
Latigo Biotherapeutics, Inc. (LTGO) reported that entities affiliated with director and ten percent owner James B. Tananbaum converted multiple preferred stock series and a convertible promissory note into common stock, largely in connection with the closing of Latigo’s initial public offering, and also purchased additional common shares. Foresite Capital funds converted an aggregate of 9,041,328 derivative-based shares into common stock through automatic conversions, and a Foresite fund separately bought 140,000 common shares at $18.00 per share. All positions are held indirectly through Foresite Capital funds, which, together with the reporting person, disclaim beneficial ownership beyond their pecuniary interests.
Latigo Biotherapeutics, Inc. (symbol LTGO) is conducting an initial public offering of 19,200,000 shares of common stock at $18.00 per share, for a gross offering size of $345.6 million, plus a 30‑day underwriters’ option to buy up to 2,880,000 additional shares. Net proceeds are estimated at $315.7 million, to fund Phase 3 development and NDA submission for acute pain candidate LTG‑001, Phase 2–3 development of chronic pain candidate LTG‑321, advancement of early‑stage Nav1.8 inhibitor LTG‑418, and general corporate purposes.
Latigo is a clinical‑stage company developing non‑opioid Nav1.8 inhibitors for acute and chronic musculoskeletal pain, with LTG‑001 showing positive abdominoplasty trial results and LTG‑321 in a Phase 2 osteoarthritis trial. The company reported a $109.2 million net loss in 2025 and had an accumulated deficit of $266.1 million, with auditors including a going‑concern explanatory paragraph.
Latigo Biotherapeutics, Inc. (LTGO) reports that several affiliated 5AM entities hold preferred stock that is convertible into Common Stock on a one-for-one basis. These are reported as indirect holdings by 5AM Ventures VI, L.P. and 5AM Opportunities II, L.P.
The Series A, Series A-2 and Series B Preferred Stock are each convertible at the option of the holder and will automatically convert into Common Stock upon closing of Latigo’s initial public offering without payment of consideration, and have no expiration date. Control and economic interest are allocated among 5AM Ventures VI, L.P., its general partner 5AM Partners VI, LLC, 5AM Opportunities II, L.P., its general partner 5AM Opportunities II (GP), LLC, and managing members Dr. Kush Parmar and Andrew J. Schwab, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest.
Latigo Biotherapeutics, Inc. (LTGO) had an initial Form 3 beneficial ownership report filed by Kevin Raidy, who is identified as a director of the company. The filing lists no reportable transactions or holdings, indicating that no equity positions are being reported at this time.
Latigo Biotherapeutics, Inc. (LTGO) reports initial holdings for director Timothy P. Walbert on a Form 3. He holds director stock options to purchase common stock with exercise prices of $2.19 and $5.53, expiring between 2034-10-29 and 2035-04-07. These options cover up to 259,770, 38,914, and 31,135 underlying shares, which vest over multi-year schedules and are early exercisable, subject to the issuer’s right of repurchase.
Latigo Biotherapeutics, Inc. (LTGO) reported initial insider holdings for Chief Medical Officer Neil Singla. He holds four employee stock options for common stock: one covering 613,468 shares at an exercise price of $2.19 expiring in 2034, and three covering 293,517, 49,480, and 98,960 shares at $5.53 expiring in 2035. Footnotes describe time-based vesting, with one-fourth vesting after one year and the remainder vesting monthly over four years.